Fundamental analysts following Honeywell (HON) have different views with one sell-side firm boosting their price target to $225 while another firm cut their recommendation to neutral with a $194 price target. Let's check out the charts and indicators of this industrial company.
More from Stocks
These recently downgraded names are displaying both quantitative and technical deterioration.
Here's how I'd play the SPDR S&P Biotech exchange-traded fund.
Trading in multiple time frames not only reduces risks, but also provides strategic flexibility. Let me show you what I mean and how to do it.
Here's why we believe 'higher for longer DUE to higher GDP' has a more dovish tone, and remain constructive for the rest of the year.